Skip to main content

Table 1 Included drugs and trials

From: Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review

Drug name Number of trials Pharmaceutical company Type of cancer Trial name available
Afatinib 6 Boehringer Ingelheim Head and neck squamous cell carcinoma, non-small cell lung cancer LUX-Head and Neck 1, LUX-Lung 5, LUX-Lung 6, LUX-Lung 8, LUX-LUNG 1
Bevacizumab 6 Roche Non-small cell lung cancer ATLAS, EURTAC, BeTa
Cabozantinib 4 Exelixis Medullary thyroid cancer, renal cell carcinoma, prostate cancer EXAM, METEOR, COMET-1, COMET-2
Cediranib 5 AstraZeneca Ovarian cancer, colorectal cancer, renal cell carcinoma, glioblastoma ICON6, HORIZON III, HORIZON II, REGAL
Cediranib 2 NCIC Clinical Trials Group Non-small cell lung cancer  
Erlotinib 1 Roche Non-small cell lung cancer  
Everolimus 1 Novartis Neuro-endocrine tumour (gastro-intestinal or lung origin) RADIANT-4
Lenvatinib 4 Eisai Non-small cell lung cancer, glioma, differentiated thyroid cancer, hepatocellular carcinoma SELECT
Nivolumab 4 Bristol-Myers Squibb Renal cell carcinoma, non-small cell lung cancer, melanoma CheckMate 025, CheckMate 057, CheckMate 067, Checkmate 069
Olaratumab 3 ImClone Systems Ovarian cancer, non-small cell lung cancer, prostate cancer  
Palbociclib 3 Pfizer Breast cancer PALOMA-2, PALOMA-3, PALOMA-4
Pembrolizumab 3 Merck Melanoma, non-small cell lung cancer Keynote-006, Keynote-010, Keynote-024